View Filing Data

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2014	Mar. 10, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	ASSEMBLY BIOSCIENCES, INC.
Entity Central Index Key	0001426800
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ASMB
Entity Common Stock, Shares Outstanding		10,695,259
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 30.5

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash	$ 29,091,113	$ 27,061,268
Other current assets	125,284	63,672
Total current assets	29,216,397	27,124,940
Property, plant and equipment, net	156,441	7,102
Security Deposit	115,005	0
Intangible assets	29,000,000	0
Goodwill	12,737,350	0
Total assets	71,225,193	27,132,042
Current liabilities
Accounts payable	907,601	2,614,619
Accrued expenses	146,420	23,435
Total current liabilities	1,054,021	2,638,054
Contingent license fee
Deferred tax liabilities	11,600,000	0
Total liabilities	12,654,021	2,638,054
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series A non-voting convertible preferred stock: 0 and 44,000 issued and outstanding at December 31, 2014 and December 31, 2013, respectively	0	44
Common stock, $0.001 par value; 50,000,000 shares authorized; 10,672,059 shares and 4,146,779 shares issued, and outstanding at December 31, 2014 and December 31, 2013, respectively	10,672	4,147
Additional paid-in capital	194,072,572	135,844,320
Common stock issuable, 0 and 125,000 shares at December 31, 2014 and December 31, 2013	0	368,750
Accumulated deficit	(135,512,072)	(111,723,273)
Total stockholders' equity	58,571,172	24,493,988
Total liabilities and stockholders' equity	$ 71,225,193	$ 27,132,042

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	10,672,059	4,146,779
Common stock, shares outstanding	10,672,059	4,146,779
Common stock issuable shares	0	125,000
Series A non-voting convertible preferred stock [Member]
Preferred stock, issued	0	44,000
Preferred stock, shares outstanding	0	44,000

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$ 10,716,737	$ 4,575,701
General and administrative	13,239,715	15,029,078
Total operating costs and expenses	23,956,452	19,604,779
Loss from operations	(23,956,452)	(19,604,779)
Other income
Interest income	167,653	201,020
Total other income	167,653	201,020
Net loss	$ (23,788,799)	$ (19,403,759)
Net loss per share, basic and diluted (In dollars per share)	$ (3.40)	$ (5.00)
Weighted average common shares outstanding, basic and diluted (In shares)	6,998,875	3,878,697

CONSOLDATED STATEMENTS OF CHANGE IN STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Issuable [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$ 17,810,186	$ 2,587	$ 0	$ 110,127,113	$ 0	$ (92,319,514)
Balance (in shares) at Dec. 31, 2012		2,586,870	0
Proceeds from common stock sold net of costs	19,204,614	$ 1,560	$ 0	19,203,054	0	0
Proceeds from common stock sold net of costs ( in Shares)		1,559,909	0
Proceeds from preferred stock sold net of costs	5,170,000	$ 0	$ 44	5,169,956	0	0
Proceeds from preferred stock sold net of costs (in Shares)		0	44,000
Restricted stock granted to four employees	368,750	$ 0	$ 0	0	368,750	0
Stock-based compensation	1,344,197	0	0	1,344,197	0	0
Net loss	(19,403,759)	0	0	0	0	(19,403,759)
Balance at Dec. 31, 2013	24,493,988	$ 4,147	$ 44	135,844,320	368,750	(111,723,273)
Balance (in shares) at Dec. 31, 2013		4,146,779	44,000
Proceeds from common stock sold net of costs	16,725,946	$ 2,051	$ 0	16,723,895	0	0
Proceeds from common stock sold net of costs ( in Shares)		2,051,472	0
Issuance of common stock for business combination	29,064,148	$ 4,009	$ 0	29,060,139	0	0
Issuance of common stock for business combination (in shares)		4,008,808	0
Issuance of common stock in exchange for restricted stock units	0	$ 25	$ 0	368,725	(368,750)	0
Issuance of common stock in exchange for restricted stock units (in shares)		25,000	0
Conversion of preferred stock to common stock	0	$ 440	$ (44)	(396)	0	0
Conversion of preferred stock to common stock (in shares)		440,000	(44,000)
Fair value of options assumed	758,948	$ 0	$ 0	758,948	0	0
Issuance of warrants for services	679,447	0	0	679,447	0	0
Stock-based compensation	10,637,494	0	0	10,637,494	0	0
Net loss	(23,788,799)	0	0	0	0	(23,788,799)
Balance at Dec. 31, 2014	$ 58,571,172	$ 10,672	$ 0	$ 194,072,572	$ 0	$ (135,512,072)
Balance (in shares) at Dec. 31, 2014		10,672,059	0

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net loss	$ (23,788,799)	$ (19,403,759)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,974	6,216
Stock-based compensation	10,637,494	1,712,947
Issuance of warrants for services	679,447	0
Changes in assets and liabilities:
Other current assets	(54,472)	(4,088)
Accounts payable	(2,481,917)	767,374
Accrued expenses	23,771	(874,778)
Net cash used in operating activities	(14,973,502)	(17,796,088)
Cash flows from investing activities
Purchase of fixed assets	(149,963)	(6,477)
Security deposits collected	(81,999)	0
Cash acquired in business combination	509,363	0
Net cash provided by (used in) investing activities	277,401	(6,477)
Cash flows from financing activities
Proceeds from issuance of common stock, net of cost	16,725,946	24,374,614
Net cash provided by financing activities	16,725,946	24,374,614
Net increase in cash	2,029,845	6,572,049
Cash at the beginning of the period	27,061,268	20,489,219
Cash at the end of the period	29,091,113	27,061,268
Supplemental schedule of non-cash financing activities
Other current assets	(23,540)	0
Equipment, net	(10,350)	0
Intangible assets	(29,000,000)	0
Goodwill	(12,737,350)	0
Security deposits	(16,606)	0
Accounts payable and accrued expenses	874,113	0
Share exchange - business combination	29,064,148	0
Fair value of vested options and restricted stock units assumed - in connection with business combination	758,948	0
Deferred tax liability	11,600,000	0
Cash acquired in business combination	509,363	0
Issuance of common stock in exchange for restricted stock units	368,750	0
Conversion of preferred stock to common stock	$ 440	$ 0

Nature of Business

12 Months Ended

Dec. 31, 2014

Organization, Business and Basis Of Presentation [Abstract]

Nature of Business

Note 1 – Nature of Business

Organization and business and basis of presentation

Assembly Biosciences, Inc. (“Assembly” or the “Company”) (formerly known as Ventrus Biosciences, Inc.) a biopharmaceutical company committed to developing novel oral therapies for the cure of intractable infectious diseases, focusing on hepatitis B virus (HBV) and C. difficile-associated infections (CDAD).

On July 11, 2014, the Company’s wholly-owned subsidiary merged with and into Assembly Pharmaceuticals, Inc. (the “Assembly Merger”), with Assembly Pharmaceuticals, Inc. (“Assembly Pharmaceuticals”) as the surviving entity. In connection with the Assembly Merger, on July 11, 2014, the Company changed its name from Ventrus Biosciences, Inc. to Assembly Biosciences, Inc.

The target of the Company’s lead program is a clinical cure for HBV, for which the Company is developing a series of new compounds, known as core protein allosteric modulators, or CpAMs, with the potential to modulate the HBV core protein—a polyfunctional essential viral protein-—at multiple complementary points in the viral lifecycle.

The Company’s CDAD program is based on the targeted delivery of novel microbiome-based therapies in a proprietary oral formulation, applying the company’s novel coating and encapsulation technology that allows for targeted delivery of complex agents to select regions of the gastrointestinal, or GI, tract. Using this proprietary delivery platform, the Company aims to deliver several types of beneficial bacteria, in novel “synthetic formats’, to the GI tract.

The Company’s consolidated financial statements include the Company’s accounts and the accounts of the Company’s wholly-owned subsidiary, Assembly Pharmaceuticals, from the date of Assembly Merger. All intercompany transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

The Company’s Board of Directors and stockholders approved a 1-for-5 reverse stock split of the Company’s common stock. The reverse stock split became effective on July 11, 2014. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.

Capital resources

The Company has not derived any revenue from product sales to date as the products have not been approved for sale by the FDA or any foreign regulatory agency. Since inception, the Company’s operations have been financed primarily through the sale of equity securities, the proceeds from the exercise of warrants and stock options and issuance of debt. The Company has incurred losses from operations and negative cash flows since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for the next twelve months. If the Company cannot generate significant cash from its operations, it intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, or other arrangements and it cannot assure such funding will be available on reasonable terms, or at all.

Summary of Significant Accounting Policies and Recent Accounting Pronouncements

12 Months Ended

Dec. 31, 2014

Summary Of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Recent Accounting Pronouncements

Note 2 - Summary of Significant Accounting Policies and Recent Accounting Pronouncements

Cash and cash equivalents

All highly liquid investments with maturities of three months or less at the time of purchase are considered to be cash equivalents. All of the Company’s cash equivalents have liquid markets and high credit ratings. The Company maintains its cash in bank deposit and other accounts, the balances of which, at times and at December 31, 2014, exceed federally insured limits.

Goodwill and Other Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in-process research and development ("IPR&D") programs acquired in the Assembly Merger, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the indefinite-lived intangible assets below their carrying values. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value

Impairment of Long-lived Assets

The Company monitors the carrying value of long-lived assets for potential impairment and tests the recoverability of such assets whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. The Company deemed there was no impairment of long-lived assets during the years ended December 31, 2014 and 2013.

Business Combinations

The Assembly Merger (see Note 3) was made at a price above the fair value of the assets acquired and liabilities assumed including deferred tax liability, resulting in goodwill, based on the Company’s expectations of synergies and other benefits of combining the acquired business. These synergies and benefits include elimination of redundant functions and staffing and use of the Company’s existing infrastructure to expand development of the product candidates of the acquired business in a cost efficient manner.

Significant judgment is required in estimating the fair value of intangible assets and in assigning their respective useful lives. The fair value estimates are based on available historical information and on future expectations and assumptions deemed reasonable by management, but which are inherently uncertain.

Net assets acquired are recorded at their fair values on the date of acquisition.

Property and Equipment

Property and equipment are stated at cost and consist of lab equipment and computer hardware and software. The Company computes depreciation under the straight-line method over the following estimated useful life of the related assets:

	⋅	Lab equipment	3 to 5 years
	⋅	Computer hardware and software	3 to 5 years

Stock-based Compensation

The Company’s share-based compensation cost is measured at grant date, using the Black-Scholes option pricing model to estimate the fair value of stock option, and is recognized as expense over the employee’s or director’s requisite service period on a straight-line basis. The Company accounts for stock options granted to non-employees on a fair value basis which is estimated using the Black-Scholes option pricing model. The initial non-cash charge to operations for non-employee options and warrants with vesting are revalued at the end of each reporting period until vested and recognized as consulting expense over the related vesting period.

On April 5, 2013, the Company granted restricted stock units to four employees under the 2010 Plan for an aggregate of 100,000 shares of common stock. Of these units, 25% vested immediately at the grant date. The Company valued the restricted stock grant, 75% of which vests in three equal installments when the 20-day trading volume weighted average price of the Company’s common stock is at least $20.75, $25.75 and $30.75, using the Monte Carlo simulation model. The unvested 75% of the units were forfeited on July 10, 2014 and the holders received options.

Warrants

For the purpose of valuing the warrants (See Note 6), the Company used the Black-Scholes option pricing model utilizing the following assumptions: Volatility - 97.3%, risk free interest rate – 1.66%, term – 5 year, exercise price - $5.13, dividends – n/a. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company’s awards. The Company estimated the expected life of the warrants based on the full term of the warrant. The expected dividend yield reflects the Company’s current and expected future policy for dividends on its common stock. The expected stock price volatility for the Company’s stock was calculated by examining historical volatilities for publicly traded industry peers as the Company did not have any trading history for its common stock at the time the grants were issued.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, fees paid to clinical research organizations and other third parties associated with clinical trials, the costs of laboratory equipment and facilities, and other external costs.

Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.

Income taxes

The Company’s income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company had adopted the provisions that tax positions must meet a “more-likely-than-not” recognition threshold to be recognized. The Company has no unrecognized tax benefits recorded for the years ended December 31, 2014 and 2013. When an accrual for interest and penalties is required, interest and penalties will be recognized in tax expense. The Company files income tax returns in the U.S. federal jurisdiction and in various states. There are currently no federal income tax examinations in process. The 2010 through 2014 tax years remain subject to examination by the Internal Revenue Service and other taxing authorities for U.S. federal and state/local tax purposes. The Company does, however, have prior year net operating losses dating back to 2007, which are subject to examination.

Loss per common share

Basic net loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Since the Company has only incurred losses, basic and diluted net loss per share is the same. Securities that could potentially dilute loss per share in the future that was not included in the computation of diluted loss per share at December 31, 2014 and 2013 are as follows:

	As of December 31,
	2014		2013
Convertible preferred stock		-		44,000
Non-vested restricted stock units		-		75,000
Warrants to purchase common stock		270,761		172,209
Options to purchase common stock		3,249,651		467,698
Total		3,520,412		758,907

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates inherent in the preparation of the accompanying financial statements include recoverability and useful lives of long-lived assets, the valuation allowance related to the Company’s deferred tax assets and the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.

Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Concentrations of Credit Risk

Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU provides for a single comprehensive model for use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for interim and annual periods beginning after December 15, 2016 with no early adoption permitted.

In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915) — Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. A public entity is required to apply the amendments for annual reporting periods beginning after December 15, 2014, and interim periods therein. An entity should apply the amendments retrospectively for all comparative periods presented. Early adoption is permitted. The guidance was adopted by the Company in the second quarter of 2014. Adoption of this standard did not have a material impact on the Company’s financial position, statement of operations, or statement of cash flows.

In June 2014, the FASB issued ASU 2014-12, Compensation-Stock Compensation (Topic 718). The ASU clarifies how entities should treat performance targets that can be achieved after the requisite service period of a share-based payment award. The accounting standard is effective for interim and annual periods beginning after December 15, 2015.

The FASB has issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance, which is effective for annual reporting periods ending after December 15, 2016, with early adoption permitted, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under GAAP. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

Assembly Pharmaceuticals, Inc. Transaction

12 Months Ended

Dec. 31, 2014

Business Combinations [Abstract]

Assembly Pharmaceuticals, Inc. Transaction

Note 3 - Assembly Pharmaceuticals, Inc. Transaction

The allocation of the purchase price to the Assembly balance sheet is shown below:

Cash and cash equivalents	$	509,363
Other current assets		23,540
Equipment, net		10,350
IPR&D		29,000,000
Goodwill		12,737,350
Security deposits		16,606
Total assets		42,297,209

Accrued expenses		874,113
Deferred tax liability		11,600,000
Total liabilities		12,474,113
Net assets acquired	$	29,823,096

The transaction was accounted for using the acquisition method. Accordingly, goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed including the related deferred tax liability.

On the acquisition date, the fair value of net assets acquired was $29,823,096. The fair value of stock issued to the Assembly Pharmaceuticals shareholders as part of the consideration of $29,064,148 was based on reference to quoted market values of the Company’s common stock as of the date of acquisition. The options assumed in the Assembly Merger were valued at approximately $758,948.

The fair value of the net assets acquired in the Assembly Merger is preliminary and is subject to change over the upcoming periods. The following table presents the unaudited pro forma financial results, as if the Assembly Merger had been completed as of January 1, 2013 and 2014.

Pro Forma

	For the Years Ended December 31,
	2014		2013
Revenues	$	-	$	-
Net loss		(26,352,751)		(20,347,860)
Loss per share - basic and diluted	$	(2.90)	$	(2.58)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Goodwill

12 Months Ended

Dec. 31, 2014

Goodwill [Abstract]

Goodwill

Note 4 - Goodwill

In July 2014, the Company completed its acquisition of Assembly Pharmaceuticals (Note 3). The fair value of consideration paid, common stock and assumed options, totaled $29,823,096, which, net of amounts allocated to assets and liabilities acquired at fair value, resulted in an allocation to goodwill of $12,737,350. The Company only has one operating segment.

Goodwill is recorded as an indefinite-lived asset and is not amortized for financial reporting purposes but is tested for impairment on an annual basis or when indications of impairment exist. No goodwill impairment losses have been recognized. Goodwill is not deductible for income tax purposes since the tax basis is $0. The Company will perform its annual impairment test of the carrying value of the Company’s goodwill each year on December 31.

No goodwill existed as of December 31, 2013. The change in the net book value of goodwill from December 31, 2013 to December 31, 2014 is shown in the table below:

As of December 31, 2013	$	-
Acquisitions		12,737,350
As of December 31, 2014	$	12,737,350

Intangible assets, net

12 Months Ended

Dec. 31, 2014

Intangible Assets Disclosure Abstract [Abstract]

Intangible assets, net

Note 5 - Intangible assets, net

In July 2014, the Company completed its acquisition of Assembly Pharmaceuticals (Notes 1 and 3). The Company acquired in-process research and development related to Assembly Pharmaceuticals’ technology which is an indefinite lived intangible asset.

No intangible assets existed as of December 31, 2013. The change in intangible assets from December 31, 2013 to December 31, 2014 is shown in the table below:

As of December 31, 2013	$	-
Acquisitions - IPR&D		29,000,000
As of December 31, 2014	$	29,000,000

Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Stockholders' Transactions [Abstract]

Stockholders' Equity

Note 6 - Stockholders’ Equity

Common and Preferred Stock Transactions

In January 2014, the Company sold an aggregate of 92,472 shares of its common stock in its amended at-the-market common equity offering program, resulting in net proceeds of approximately $1,763,000 or $19.07 per share.

In February 2014, all 44,000 outstanding shares of the Company’s Series A non-voting convertible preferred stock converted into an aggregate 440,000 shares of common stock.

In July 2014, the Company issued 25,000 shares of common stock upon vesting of the restricted stock units.

On October 6, 2014, the Company sold to various institutional investors an aggregate of 1,959,000 shares of common stock in a registered direct offering. The purchase price paid by the investors was $8.04 per share and an aggregate of approximately $14,963,000 in net proceeds were received. In connection with the offering, the Company entered into a placement agent agreement with William Blair & Company, L.L.C., who acted as sole placement agent in the offering, and pursuant to which the Company paid a placement agent fee equal to 5.0% of the gross proceeds of the offering.

Reverse Stock Split

Assembly Merger

On July 11, 2014, the Company completed the Assembly Merger, whereby Assembly Pharmaceuticals became the Company’s wholly-owned subsidiary. Pursuant to the terms of the Assembly Merger, the shares of Assembly Pharmaceuticals, common stock issued and outstanding were converted into an aggregate of 4,008,848 shares of the Company’s common stock. Also pursuant to the terms of the Assembly Merger, the options to purchase shares of Assembly Pharmaceuticals common stock issued and outstanding immediately prior to the Assembly Merger were assumed by the Company and became exercisable for an aggregate of 621,651 shares of the Company’s common stock. The fully vested assumed options in the Assembly Merger were valued at $758,948 using the Black-Scholes model. The fair value of the options was recorded as a component of stockholders’ equity. The fair value of the options was determined using the Black-Scholes model with the following assumptions: risk free interest rate - 1.66% - 2.15%, volatility - 97.33% - 102.8%, expected term 5 - 6.1 years, expected dividends- N/A.

Options, Warrants and Restricted Stock Units:

Options

The Company has two equity incentive plans available for the granting of equity awards. In July 2014, the stockholders approved the 2014 Stock Incentive Plan, under which, as of December 31, 2014, there were options for an aggregate of 2,560,000 shares of common stock outstanding and no shares available for grant.

Prior to July 10, 2014, the Company’s stockholders had approved the 2010 Stock Plan. The Company also had outstanding on July 10, 2014, options to purchase 403 shares of common stock issued pursuant to its 2006 Stock Plan which plan was terminated in 2010. From January 1, 2014 to July 10, 2014, an aggregate of 57,953 options were forfeited and on July 10, 2014, all of the Company’s directors and employees forfeited an additional aggregate of 514,445 options. Through July 10, 2014, an aggregate of 122,700 options to acquire the Company’s Common Stock was granted to employees. Also on July 10, 2014, Company’s stockholders approved the 2014 Stock Incentive Plan, under which an aggregate of 2,560,000 shares of the Company’s common stock is reserved for the issuance of equity awards to employees, directors and consultants of the Company and its subsidiaries. On July 10, 2014, the Company granted all of these options to various employees and directors with an exercise price of $7.20 and which vest one third on the date of grant, one third on the first anniversary of the option grant date and one third on the second anniversary of the option grant date. The cancellation and reissuance of these stock options was treated as a modification and, accordingly, total stock-based compensation expense related to these awards increased $15,003,740, which will be recognized over the new vesting period. The options assumed on the Assembly Merger are outside the Company’s stock option plans.

On July 10, 2014, Dr. Felder ceased to be a director and 11,800 options vested on July 10, 2014. These 11,800 options subsequently expired 90 days after termination of his board service in 2014.

A summary of the Company’s option activity under its option plans and related information is as follows:

	Number of Shares	Weighted Average Exercise Price		Total Intrinsic Value
Outstanding as of December 31, 2013	467,698	$	29.35	$	-
Assumed	621,651		2.22		3,506,112
Granted	2,750,700		7.75		1,689,600
Forfeited	(590,398)		26.84		-
Expired	(11,800)		7.20		-
Outstanding as of December 31, 2014	3,249,651	$	6.26	$	5,187,924
Options vested and exercisable	1,086,425	$	6.17	$	1,832,125

The Company expects that all outstanding unvested options will vest. The fair value of the options granted for the year ended December 31, 2014 and 2013, was based on the following assumptions:

	Year ended December 31,
	2014		2013
Exercise price		$2.22 - $8.13		$12.35 - $16.55
Expected stock price volatility		94.37% - 105.03%		59.32% - 77.34%
Risk-free rate of interest		1.65% - 2.53%		1.23% - 2.34%
Term (years)		4.9 - 10.0		7

Estimated future employees’ stock-based compensation expense relating to unvested stock options is as follows:

	Future Stock Option Compensation Expenses
2015		6,280,264
2016		1,703,957
2017		34,943
Total	$	8,019,164

The weighted average remaining contractual life of options outstanding at December 31, 2014 is approximately 9.5 years.

Stock-based compensation expensed to research and development expense for the years ended December 31, 2014 and 2013 was $2,707,337 and $695,636, respectively. Stock-based compensation expensed to general and administrative expense for the years ended December 31, 2014 and 2013 was $7,930,157 and $1,017,311, respectively.

Warrants

In connection with the Company’s financings from 2007 to 2010, the Company issued warrants to investors and/or placement agents, as well as certain consultants, to purchase shares of common stock. In connection with the Assembly Merger, the Company issued warrants to purchase up to 120,265 shares of its common stock to its financial advisor for the Assembly Merger. The warrants were valued at $679,447 and expensed during the quarter ended September 30, 2014.

A summary of the Company’s warrant activity and related information is as follows:

	Warrants		Weighted Average Exercise Price
Outstanding as of December 31, 2013		172,209	$	38.85
Issued		120,265		5.13
Expired		(21,713)		33.00
Outstanding as of December 31, 2014		270,761	$	24.34
Exercisable as of December 31, 2014		270,761	$	24.34

Restricted Stock Units

On April 5, 2013, the Company granted restricted stock units to four employees under the 2010 Plan for an aggregate of 100,000 shares of common stock. Of these units, 25% vested immediately at the grant date. The remaining 75% of the units were forfeited on July 10, 2014 and the holders received options (see options above).

A summary of the status of our restricted stock units as of December 31, 2014 is as follows:

	Number of Shares	Weighted Average Exercise Price
Outstanding as of December 31, 2013	75,000	$	10.20
Forfeited	(75,000)		10.20
Outstanding as of December 31, 2014	-	$	-

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

Note 7 - Income Taxes

There was no current or deferred income tax provision for the years ended December 31, 2014 and 2013.

The Company’s deferred tax assets as of December 31 consist of the following:

	As of December 31,
	2014		2013
Deferred tax assets:
Net-operating loss carryforward	$	38,094,000	$	32,193,000
Stock-based compensation		11,691,000		6,617,000
In-Process R&D		5,697,000		6,017,000
R&D credit		2,600,000		2,149,000
Other		2,000		-

Total Deferred Tax Assets		58,084,000		46,976,000
Valuation allowance		(58,084,000)		(46,976,000)
Deferred Tax Asset, Net of	$	-	$	-
In-process research and development (Assembly Merger)		11,600,000		-
Deferred Tax Liability	$	11,600,000	$	-

The Company recognized a $11,600,000 deferred tax liability in 2014 as a result of the acquisition of Assembly Pharmaceuticals in July 2014. Due to the acquisition, a temporary difference between the book fair value and the tax basis of the other in-process research and development acquired created an approximately $11,600,000 deferred tax liability and additional goodwill was recorded.

At December 31, 2014, the Company had potentially utilizable gross Federal net operating loss carry-forwards of approximately $86,551,323, State net operating loss carry-forwards of approximately $79,958,236 and research and development credit carry forward of approximately $2,600,174, all of which expire between 2027 and 2031.

An ownership change under Internal Revenue Code (“IRC”) Section 382 could have occurred due to common stock issued in the IPO and debt conversions in December 2010 and also in the Assembly Merger in July 2014. Due to the change in ownership provisions of the IRC, the availability of the Company’s net operating loss carry forwards could be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carry forwards. As of now, the Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership. The Company will undertake to perform an IRC 382 study within the next year to determine the extent of a limitation. The effects of the study could cause a significant reduction in the deferred tax asset with an offsetting reduction in the valuation allowance.

	For the years ended December 31,
	2014		2013
Statutory Federal Income Tax Rate	(34.0)	%	(34.0)	%
State Taxes, Net of Federal Tax Benefit	(11.0)	%	(11.0)	%
Change in Valuation Allowance	45.0	%	45.0	%

Income Taxes Provision (Benefit)	0.0	%	0.0	%

License Agreements

12 Months Ended

Dec. 31, 2014

License Arrangement [Abstract]

License Agreements

Note 8 - License Agreements

HBV Research Agreement with Indiana University

The Company, through its wholly-owned subsidiary, Assembly Pharmaceuticals, is party to a license agreement with Indiana University Research and Technology Corporation (“IURTC”) from whom it has licensed the Company’s HBV therapy. The license agreement requires the Company to make milestone payments based upon the successful accomplishment of clinical and regulatory milestones related to the HBV therapy. The total amount of all potential future milestone payments at December 31, 2014 is $825,000. The Company also is obligated to pay IURTC royalty payments based on net sales of the licensed technology. The Company is also obligated to pay diligence maintenance fees (starting at $25,000 in 2014 and rising to $100,000 in the year following first commercial sale of licensed product) each year to the extent that the royalty, sublicensing, and milestone payments to IURTC are less than the diligence maintenance fee for that year.

Microbiome Targeted Colonic Delivery Platform

On November 8, 2013, Assembly entered into a License and Collaboration Agreement with Therabiome, LLC, for all intellectual property and know-how owned or controlled by Therabiome relating to the oral delivery of pharmaceutical drugs to specific sites in the intestine, using a pH sensitive controlled release platform technology. Under the agreement, Therabiome granted to Assembly the exclusive worldwide license, with rights to sublicense, to develop the intellectual property for commercialization (a) in the use of bacteria, viruses, proteins and small molecules by oral delivery in (i) gastro- intestinal dysbiosis, including but not limited to C. difficile, irritable bowel syndrome-constipation and inflammatory bowel disease, (ii) auto-immune disorders and autism, including but not limited to as controlled by bacteria or virus, and (iii) orally delivered vaccines, including viral and bacterial, and (b) any oral delivery of small molecules using the licensed intellectual property. Assembly will be solely responsible for all research and development activities with respect to any product it develops under the license.

For the license, Assembly paid Therabiome an upfront non-refundable license fee of $300,000. Assembly must pay Therabiome clinical and regulatory milestones for each product or therapy advanced from the platform for U.S. regulatory milestones. Assembly also must pay Therabiome lesser amounts for foreign regulatory milestones, which vary by country and region. Assembly also must pay Therabiome royalties on annual net sales of a product in the low to mid-single digit percentages plus, once annual net sales exceed two certain thresholds, a one-time cash payment upon reaching each threshold.

Therabiome must pay Assembly royalties on annual net sales of any product it develops, using the intellectual property, in the low double to mid-double digit percentages, depending on the level of development or involvement Assembly had in the product.

Diltiazem (VEN 307) and Phenylepherine (VEN 308)

The Company had an exclusive royalty-bearing license agreement with S.L.A. Pharma, AG (“S.L.A. Pharma”) to sell, make and use diltiazem (VEN 307) for treatment, through topical administration, of anal fissures and phenylepherine (VEN 308) for treatment, through topical administration, of fecal incontinence (referred to collectively as the “Compound Technologies”) in the United States, Canada and Mexico. In the event that the Compound Technologies were commercialized, Assembly was obligated to pay to S.L.A. Pharma annual royalties, based upon net sales of the products. In addition, Assembly was required to make payments to S.L.A. Pharma up to an aggregate amount of $20 million upon the achievement of various milestones related to regulatory events.

On July 24, 2014, the Company notified S.L.A. Pharma that it was terminating the license agreement. The termination was effective on October 22, 2014. There were no early termination penalties as a result of the termination and the Company has no continuing obligation to make payment to S.L.A. Pharma under the agreement. The Company terminated the agreement to focus on the development of its potentially curative programs for HBV, which program was acquired on July 11, 2014 in the merger with Assembly Pharmaceuticals, Inc., and CDAD, which was licensed in November 2013 from Therabiome, LLC.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9 - Commitments and Contingencies

Lease

As of December 31, 2014, the Company had offices in New York, NY with an $8,400 monthly payment. The lease expires in September 2015.

In January 2015, the Company entered into a lease in San Francisco, CA with an $36,145 monthly payment. The lease expires in December 2016.

Employment agreements

On January 15, 2014, the Company entered into an employment agreement with each of its Chief Executive Officer and its Chief Financial Officer, with an effective date of December 22, 2013. Each agreement has a term of two years and will be automatically extended for additional one-year periods unless the Company notifies the officer at least 180 days prior to the then current expiration date that it intends to not extend the employment agreement. The employment agreements provide for a base salary of $475,000 per year for the Chief Executive Officer and $300,000 for the Chief Financial Officer, and an annual discretionary bonus of up to 50% of the officer’s base salary based on financial, clinical development and business milestones established by the Board of Directors. In connection with the Assembly Merger, the Company amended the Chief Executive Officer’s employment agreement. Pursuant to the amendment, the Chief Executive Officer will continue to serve as the Company’s Chief Executive Officer. However, after the Assembly Merger, at any time the Company’s Board may appoint the Company’s President and Chief Operating Officer as Chief Executive Officer. In such event, the Chief Executive Officer will become the Executive Chair, and his employment as Chief Executive Officer will end. In December 2014, the compensation committee approved a change of base salary to $350,000 per year for the Chief Financial Officer.

In connection with the Assembly Merger, effective July 11, 2014, the Company entered into employment agreements with its President and Chief Operating Officer, its Chief Medical Officer, and its Chief Scientific Officer. The President’s employment agreement has a term of two years and will be automatically extended for additional one-year periods unless the Company notifies the President at least 180 days prior to the then current expiration date that it intends to not extend the employment agreement. The other two employment agreements provide for at-will employment, subject to payment of severance benefits depending on the circumstances of termination. The employment agreements provide for a base salary of $350,000 per year for the President, $290,000 per year for the Chief Medical Officer and $315,000 per year for the Chief Scientific Officer. Each employee is also eligible for an annual discretionary bonus based on achievement of financial, clinical development and business milestones established by the Board of Directors, with the President eligible for a bonus of up to 50% of his base salary, and the Chief Medical Officer and the Chief Scientific Officer eligible for a bonus of up to 30% of their respective base salaries. The President and the Chief Medical Officer also received a retention bonus payable after three months of employment in the amount of $150,000 and $100,000, respectively.

Litigation

In June 2012, the Company announced that its product iferanserin (VEN 309), failed to meet its end point at the completion of its Phase III clinical trial. In May 2013 two purported class action lawsuits alleging violations of the federal securities laws were filed in New York against the Company, two of its executive officers and the lead underwriter of its initial public offering. The lawsuits included allegations that, during the class period between December 17, 2010 and June 25, 2012, the Company and its executive officers and underwriter made various statements related to the Company’s product, iferanserin (VEN 309), including but not limited to, the market for the product, the potential competitors, and the results of clinical trials, thereby inflating the price of our common stock. The complaints sought unspecified damages, interest, attorneys’ fees, and other costs. On July 23, 2013, the Court consolidated the actions and appointed lead plaintiffs and lead counsel. On September 16, 2013, lead plaintiffs filed a consolidated amended complaint. On November 22, 2013, the Company filed a motion to dismiss the consolidated amended complaint (the “Motion to Dismiss”).

On May 5, 2014, the Court granted the Motion to Dismiss and dismissed the class action with prejudice.

On May 19, 2014, lead plaintiffs filed a Motion for Reconsideration of the Court’s order dismissing the class action with prejudice (the “Motion for Reconsideration”). On July 2, 2014, the Court entered an order denying the Motion for Reconsideration. Lead plaintiffs had until August 2, 2014 to file notice of an appeal, but no appeal was filed.

Subsequent Event

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Events

Note 10- Subsequent Event

On February 10, 2015, the Company named Mr. Small its Chief Executive Officer, in addition to his current position as President, and named Mr. Barrett its Chief Operating Officer, in addition to his current role as Chief Financial Officer. In his new position, Mr. Small received a 20% salary increase, bringing his salary to $420,000, and for his additional responsibility, Mr. Barrett receive a 3% salary increase, bring his salary to $360,500. As had been agreed during the Assembly Merger, Mr. Small succeeded Dr. Ellison as the Company’s Chief Executive Officer. At the same time, the Company’s current director William Ringo succeeded Dr. Ellison as Chairman. Dr. Ellison will continue to serve the Company as a director until the 2015 annual meeting, and he will also continue as a Senior Advisor and head of the Company’s microbiome development program. The succession constitutes a “termination without cause” under Dr. Ellison’s employment agreement. As a result, subject to Dr. Ellison signing a release agreement and the passage of the required revocation period provided therein, Dr. Ellison will be entitled to 12 months of salary, immediate vesting of an additional one third of his outstanding options an extension of the exercise period (which would otherwise have been shortened to 90 days subsequent to his termination) to the option expiration date of July 10, 2024, and reimbursement of COBRA premiums for 12 months or until he is eligible for insurance benefits from another employer, whichever is earlier.

Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)

12 Months Ended

Dec. 31, 2014

Summary Of Significant Accounting Policies [Abstract]

Cash and cash equivalents

Cash and cash equivalents

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

Impairment of Long-lived Assets

Impairment of Long-lived Assets

Business Combinations

Business Combinations

Net assets acquired are recorded at their fair values on the date of acquisition.

Property and Equipment

Property and Equipment

	⋅	Lab equipment	3 to 5 years
	⋅	Computer hardware and software	3 to 5 years

Stock-based Compensation

Stock-based Compensation

Warrants

Warrants

Research and Development Costs

Research and Development Costs

Income taxes

Income taxes

Loss per common share

Loss per common share

	As of December 31,
	2014		2013
Convertible preferred stock		-		44,000
Non-vested restricted stock units		-		75,000
Warrants to purchase common stock		270,761		172,209
Options to purchase common stock		3,249,651		467,698
Total		3,520,412		758,907

Use of estimates

Use of estimates

Concentrations of Credit Risk

Concentrations of Credit Risk

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)

12 Months Ended

Dec. 31, 2014

Summary Of Significant Accounting Policies [Abstract]

Property, Plant and Equipment

	⋅	Lab equipment	3 to 5 years
	⋅	Computer hardware and software	3 to 5 years

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Securities that could potentially dilute loss per share in the future that was not included in the computation of diluted loss per share at December 31, 2014 and 2013 are as follows:

	As of December 31,
	2014		2013
Convertible preferred stock		-		44,000
Non-vested restricted stock units		-		75,000
Warrants to purchase common stock		270,761		172,209
Options to purchase common stock		3,249,651		467,698
Total		3,520,412		758,907

Assembly Pharmaceuticals, Inc. Transaction (Tables)

12 Months Ended

Dec. 31, 2014

Assembly Pharmaceuticals, Inc. Transaction [Abstract]

Assembly Pharmaceuticals, Inc. Transaction

The allocation of the purchase price to the Assembly balance sheet is shown below:

Cash and cash equivalents	$	509,363
Other current assets		23,540
Equipment, net		10,350
IPR&D		29,000,000
Goodwill		12,737,350
Security deposits		16,606
Total assets		42,297,209

Accrued expenses		874,113
Deferred tax liability		11,600,000
Total liabilities		12,474,113
Net assets acquired	$	29,823,096

Pro Forma

	For the Years Ended December 31,
	2014		2013
Revenues	$	-	$	-
Net loss		(26,352,751)		(20,347,860)
Loss per share - basic and diluted	$	(2.90)	$	(2.58)

Goodwill (Tables)

12 Months Ended

Dec. 31, 2014

Goodwill [Abstract]

Schedule Of Goodwill Acquisition

The change in the net book value of goodwill from December 31, 2013 to December 31, 2014 is shown in the table below:

As of December 31, 2013	$	-
Acquisitions		12,737,350
As of December 31, 2014	$	12,737,350

Intangible assets, net (Tables)

12 Months Ended

Dec. 31, 2014

Intangible Assets Disclosure Abstract [Abstract]

Schedule of Indefinite-Lived Intangible Assets

The change in intangible assets from December 31, 2013 to December 31, 2014 is shown in the table below:

As of December 31, 2013	$	-
Acquisitions - IPR&D		29,000,000
As of December 31, 2014	$	29,000,000

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Assumptions for Weighted Average Fair Value of Options Granted

The Company expects that all outstanding unvested options will vest. The fair value of the options granted for the year ended December 31, 2014 and 2013, was based on the following assumptions:

	Year ended December 31,
	2014		2013
Exercise price		$2.22 - $8.13		$12.35 - $16.55
Expected stock price volatility		94.37% - 105.03%		59.32% - 77.34%
Risk-free rate of interest		1.65% - 2.53%		1.23% - 2.34%
Term (years)		4.9 - 10.0		7

Estimated Future Stock Based Expenses Relating to Unvested Stock Options

Estimated future employees’ stock-based compensation expense relating to unvested stock options is as follows:

	Future Stock Option Compensation Expenses
2015		6,280,264
2016		1,703,957
2017		34,943
Total	$	8,019,164

Schedule of Restricted Stock Units

A summary of the status of our restricted stock units as of December 31, 2014 is as follows:

	Number of Shares	Weighted Average Exercise Price
Outstanding as of December 31, 2013	75,000	$	10.20
Forfeited	(75,000)		10.20
Outstanding as of December 31, 2014	-	$	-

Stock Option [Member]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s option activity under its option plans and related information is as follows:

	Number of Shares	Weighted Average Exercise Price		Total Intrinsic Value
Outstanding as of December 31, 2013	467,698	$	29.35	$	-
Assumed	621,651		2.22		3,506,112
Granted	2,750,700		7.75		1,689,600
Forfeited	(590,398)		26.84		-
Expired	(11,800)		7.20		-
Outstanding as of December 31, 2014	3,249,651	$	6.26	$	5,187,924
Options vested and exercisable	1,086,425	$	6.17	$	1,832,125

Warrant [Member]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s warrant activity and related information is as follows:

	Warrants		Weighted Average Exercise Price
Outstanding as of December 31, 2013		172,209	$	38.85
Issued		120,265		5.13
Expired		(21,713)		33.00
Outstanding as of December 31, 2014		270,761	$	24.34
Exercisable as of December 31, 2014		270,761	$	24.34

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities

The Company’s deferred tax assets as of December 31 consist of the following:

	As of December 31,
	2014		2013
Deferred tax assets:
Net-operating loss carryforward	$	38,094,000	$	32,193,000
Stock-based compensation		11,691,000		6,617,000
In-Process R&D		5,697,000		6,017,000
R&D credit		2,600,000		2,149,000
Other		2,000		-

Total Deferred Tax Assets		58,084,000		46,976,000
Valuation allowance		(58,084,000)		(46,976,000)
Deferred Tax Asset, Net of	$	-	$	-
In-process research and development (Assembly Merger)		11,600,000		-
Deferred Tax Liability	$	11,600,000	$	-

Federal Income Tax Note

The effects of the study could cause a significant reduction in the deferred tax asset with an offsetting reduction in the valuation allowance.

	For the years ended December 31,
	2014		2013
Statutory Federal Income Tax Rate	(34.0)	%	(34.0)	%
State Taxes, Net of Federal Tax Benefit	(11.0)	%	(11.0)	%
Change in Valuation Allowance	45.0	%	45.0	%

Income Taxes Provision (Benefit)	0.0	%	0.0	%

Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2014
Maximum [Member] \| Lab equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] \| Computer hardware and software [Member]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] \| Lab equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] \| Computer hardware and software [Member]
Property, Plant and Equipment, Useful Life	3 years

Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Loss Per Common Share) (Details) - shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,520,412	758,907
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	44,000
Non Vested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	75,000
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	270,761	172,209
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,249,651	467,698

Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details) - $ / shares		1 Months Ended	12 Months Ended
	Apr. 05, 2013	Jul. 11, 2014	Dec. 31, 2014
Percentage Of Restricted Stock Units Vested Descriptions			The Company valued the restricted stock grant, 75% of which vests in three equal installments when the 20-day trading volume weighted average price of the Company’s common stock is at least $20.75, $25.75 and $30.75, using the Monte Carlo simulation model.
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross			2,750,700
Warrant [Member]
Fair Value Assumptions, Expected Volatility Rate		97.30%
Fair Value Assumptions, Risk Free Interest Rate		1.66%
Fair Value Assumptions, Expected Term		5 years
Fair Value Assumptions, Exercise Price		$ 5.13
Maximum [Member]
Fair Value Assumptions, Expected Volatility Rate		102.80%
Fair Value Assumptions, Risk Free Interest Rate		2.15%
Fair Value Assumptions, Expected Term		6 years 1 month 6 days
Minimum [Member]
Fair Value Assumptions, Expected Volatility Rate		97.33%
Fair Value Assumptions, Risk Free Interest Rate		1.66%
Fair Value Assumptions, Expected Term		5 years
Restricted Stock Units (RSUs) [Member] \| 2010 Plan
Percentage Of Restricted Stock Units Vested Descriptions	Of these units, 25% vested immediately at the grant date. The remaining 75% of the units were forfeited on July 10, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	75.00%
Share Based Compensation Arrangement By Share Based Payment Award Number Of Employees	four

Assembly Pharmaceuticals, Inc. Transaction - Allocation of Purchase Price (Details) - USD ($)	Dec. 31, 2014	Jul. 11, 2014	Dec. 31, 2013
Cash and cash equivalents		$ 509,363
Other current assets		23,540
Equipment, net		10,350
IPR&D		29,000,000
Goodwill		12,737,350
Security deposits	$ 115,005	16,606	$ 0
Total assets		42,297,209
Accrued expenses		874,113
Deferred tax liability		11,600,000
Total liabilities		12,474,113
Consideration Paid
Net assets acquired		$ 29,823,096

Assembly Pharmaceuticals, Inc. Transaction - Pro Forma (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Pro Forma
Revenues	$ 0	$ 0
Net loss	$ (26,352,751)	$ (20,347,860)
Loss per share - basic and diluted	$ (2.90)	$ (2.58)

Assembly Pharmaceuticals, Inc. Transaction - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 11, 2014	Dec. 31, 2014	Dec. 31, 2013
Stock Issued During Period, Shares, Conversion of Convertible Securities	4,008,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	621,651	1,086,425
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	$ 29,823,096
Fair value of options assumed	758,948	$ 758,948	$ 0
Noncash Or Part Noncash Acquisition Share Exchange Business Combination	$ 29,064,148	$ 29,064,148	$ 0

Goodwill - Change in the Net Book Value of Goodwill (Details)	12 Months Ended
	Dec. 31, 2014 USD ($)
As of December 31,2013	$ 0
Acquisitions	12,737,350
As of December 31, 2014	$ 12,737,350

Goodwill - Additional Information (Details)	12 Months Ended
Goodwill - Additional Information (Details)	Dec. 31, 2014 USD ($)
Business Combination, Consideration Transferred	$ 29,823,096
Allocation of goodwill	12,737,350
Business Acquisition, Goodwill, Expected Tax Deductible Amount	$ 0

Intangible assets, net - Change In Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2014 USD ($)
As of December 31, 2013	$ 0
Acquisitions - IPR&D	29,000,000
As of December 31, 2014	$ 29,000,000

Stockholders' Equity - Option Activity and Related Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Jul. 11, 2014
Shares
Option, Outstanding at beginning of period	467,698
Option Assumed	621,651
Option, Granted	2,750,700
Option, Forfeited	(590,398)
Option, Expired	(11,800)
Option, Outstanding at end of period	3,249,651
Options vested and exercisable	1,086,425	621,651
Weighted Average Exercise Price
Option, Outstanding at beginning of period	$ 29.35
Option Assumed	2.22
Option, Granted	7.75
Option, Forfeited	26.84
Option, Expired	7.20
Option, Outstanding at end of period	6.26
Option vested exercisable at end of period	$ 6.17
Aggregate Intrinsic Value
Option, Outstanding at beginning of period	$ 0
Option Assumed	3,506,112
Option, Granted	1,689,600
Option, Forfeited	0
Option, Expired	0
Option, Outstanding at end of period	5,187,924
Option vested exercisable at end of period	$ 1,832,125

Stockholders' Equity - Assumptions for Fair Value of Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Term (years)		7 years
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Exercise price	$ 8.13	$ 16.55
Expected stock price volatility	105.03%	77.34%
Risk-free rate of interest	2.53%	2.34%
Term (years)	10 years
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Exercise price	$ 2.22	$ 12.35
Expected stock price volatility	94.37%	59.32%
Risk-free rate of interest	1.65%	1.23%
Term (years)	4 years 10 months 24 days

Stockholders' Equity - Estimated Future Stock-Based Compensation Expense Relating to Unvested Stock Options (Details)	Dec. 31, 2014 USD ($)
Stockholders Equity Note [Line Items]
2015	$ 6,280,264
2016	1,703,957
2017	34,943
Total	$ 8,019,164

Stockholders' Equity - Warrant Activity and Related Information (Details)	12 Months Ended
	Dec. 31, 2014 $ / shares shares
Shares
Warrants, at beginning of period \| shares	172,209
Warrants, Issued \| shares	120,265
Warrants, Expired \| shares	(21,713)
Warrants, at end of period \| shares	270,761
Warrants, Exercisable \| shares	270,761
Weighted Average Exercise Price
Warrants, at beginning of period \| $ / shares	$ 38.85
Warrants, Issued \| $ / shares	5.13
Warrants, Expired \| $ / shares	33.00
Warrants, at end of period \| $ / shares	24.34
Warrants, Exercisable \| $ / shares	$ 24.34

Stockholders' Equity - Summary Of Restricted Stock Units (Details)	12 Months Ended
	Dec. 31, 2014 $ / shares shares
Shares
Restricted stock units, Outstanding at beginning of period \| shares	75,000
Restricted stock units, Forfeited \| shares	(75,000)
Restricted stock units, Outstanding at end of period \| shares	0
Weighted Average Exercise Price
Restricted stock units, Outstanding at beginning of period \| $ / shares	$ 10.20
Restricted stock units, Forfeited \| $ / shares	10.20
Restricted stock units, Outstanding at end of period \| $ / shares	$ 0

Stockholders' Equity - Additional Information (Details) - USD ($)						1 Months Ended			12 Months Ended
	Nov. 11, 2014	Oct. 06, 2014	Jul. 11, 2014	Jul. 10, 2014	Apr. 05, 2013	Jul. 31, 2014	Jul. 11, 2014	Jan. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2014
Stockholders Equity Note [Line Items]
Net proceeds raised from common stock issued in a public offering		$ 14,963,000
Stock based compensation expense				$ 15,003,740
Percentage Of Restricted Stock Units Vested Descriptions									The Company valued the restricted stock grant, 75% of which vests in three equal installments when the 20-day trading volume weighted average price of the Company’s common stock is at least $20.75, $25.75 and $30.75, using the Monte Carlo simulation model.
Stock Issued During Period, Shares, New Issues		1,959,000
Stock Issued During Period, Shares, Conversion of Convertible Securities							4,008,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			621,651				621,651		1,086,425
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number									3,249,651	467,698
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period				514,445
Common Stock, Capital Shares Reserved for Future Issuance				2,560,000
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price				$ 7.20					$ 6.26	$ 29.35
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period									120,265
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term									9 years 6 months
Stockholders' Equity, Reverse Stock Split			The Company’s Board of Directors and stockholders approved a 1-for-5 reverse stock split of the Company’s common stock. The reverse stock split became effective on July 11, 2014. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.
Fair value of options assumed							$ 758,948		$ 758,948	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares				57,953
Issuance of Stock and Warrants for Services or Claims									$ 679,447	0
Sale of Stock, Price Per Share		$ 8.04
Percentage Of Placement Agent Fee		5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				11,800
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms	13,000 of these options vest one third on the date of grant, one third on the first anniversary of the option grant date and one third on the second anniversary of the option grant date. The other 55,000 options vest one third on the first anniversary of the option grant date, one third on the second anniversary of the option grant date and one third on the third anniversary of the option grant date.
Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period Shares In Exchange For Restricted Stock Units									0
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred Stock, Shares Outstanding											44,000
Convertible Preferred Stock, Shares Issued upon Conversion											440,000
Common Stock [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Value, New Issues								$ 1,763,000
Stock Issued During Period, Shares, New Issues								92,472
Sale of Stock, Price Per Share								$ 19.07
Stock Issued During Period Shares In Exchange For Restricted Stock Units						25,000			25,000
Sl Pharma [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			621,651				621,651
Maximum [Member]
Stockholders Equity Note [Line Items]
Fair Value Assumptions, Expected Volatility Rate							102.80%
Fair Value Assumptions, Risk Free Interest Rate							2.15%
Fair Value Assumptions, Expected Term							6 years 1 month 6 days
Minimum [Member]
Stockholders Equity Note [Line Items]
Fair Value Assumptions, Expected Volatility Rate							97.33%
Fair Value Assumptions, Risk Free Interest Rate							1.66%
Fair Value Assumptions, Expected Term							5 years
Research and Development Expense [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense									$ 2,707,337	695,636
General and Administrative Expenses [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense									$ 7,930,157	$ 1,017,311
Restricted Stock Units (RSUs) [Member]
Stockholders Equity Note [Line Items]
Share Based Compensation Arrangement By Share based Payment Award Percentage Of Units Forfeited					75.00%
Restricted Stock Units (RSUs) [Member] \| 2010 Plan
Stockholders Equity Note [Line Items]
Percentage Of Restricted Stock Units Vested Descriptions					Of these units, 25% vested immediately at the grant date. The remaining 75% of the units were forfeited on July 10, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%
Restricted Stock Units (RSUs) [Member] \| Four Employees [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					100,000
2014 Stock Incentive Plan [Member]
Stockholders Equity Note [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number									2,560,000
2014 Stock Incentive Plan [Member] \| Employees [Member]
Stockholders Equity Note [Line Items]
Stock options granted				122,700
2006 Stock Plan [Member]
Stockholders Equity Note [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number				403

Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net-operating loss carryforward	$ 38,094,000	$ 32,193,000
Stock-based compensation	11,691,000	6,617,000
In-Process R&D	5,697,000	6,017,000
R&D credit	2,600,000	2,149,000
Other	2,000	0
Total Deferred Tax Assets	58,084,000	46,976,000
Valuation allowance	(58,084,000)	(46,976,000)
Deferred Tax Asset, Net of	0	0
In-process research and development (Assembly Merger)	11,600,000	0
Deferred Tax Liability	$ 11,600,000	$ 0

Income Taxes - Effective Income Tax Rate (Details)	12 Months Ended
Income Taxes - Effective Income Tax Rate (Details)	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax [Line Items]
Statutory Federal Income Tax Rate	(34.00%)	(34.00%)
State Taxes, Net of Federal Tax Benefit	(11.00%)	(11.00%)
Change in Valuation Allowance	45.00%	45.00%
Income Taxes Provision (Benefit)	0.00%	0.00%

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Deferred Tax Liabilities, Net	$ 11,600,000	$ 0
Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs	11,600,000	$ 0
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	79,958,236
Deferred Tax Assets, Tax Credit Carryforwards, Research	2,600,174
Deferred Tax Assets, Operating Loss Carryforwards, Federal	$ 86,551,323
Maximum [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards Expiration Period	2031
Minimum [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards Expiration Period	2027

License Agreements - Additional Information (Details)	12 Months Ended
License Agreements - Additional Information (Details)	Dec. 31, 2014 USD ($)
Indiana University Research and Technology Corporation [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential milestone payment	$ 825,000
Indiana University Research and Technology Corporation [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Diligence maintenance fees Obligation	100,000
Indiana University Research and Technology Corporation [Member] \| Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Diligence maintenance fees Obligation	25,000
S.L.A. Pharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential milestone payment	20,000,000
Therabiome, LLC [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment For Nonrefundable License Fee	$ 300,000

Commitments and Contingencies - Additional Information (Details) - USD ($)		1 Months Ended		12 Months Ended
	Feb. 10, 2015	Jan. 31, 2015	Jul. 11, 2014	Dec. 31, 2014
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense				$ 8,400
Subsequent Event [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense		$ 36,145
Chief Executive Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual base Salary				475,000
Chief Executive Officer [Member] \| Subsequent Event [Member]
Commitments and Contingencies Disclosure [Line Items]
Officers' Compensation	$ 420,000
Chief Financial Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual base Salary				$ 300,000
Annual performance-based bonus, percentage				50.00%
Officers' Compensation				$ 350,000
Chief Business Officer [Member] \| Subsequent Event [Member]
Commitments and Contingencies Disclosure [Line Items]
Officers' Compensation	$ 360,500
President [Member]
Commitments and Contingencies Disclosure [Line Items]
Labor and Related Expense			$ 350,000
Maximum Percentage Of Bonus From Base Salary			50.00%
Retention Bonus Payable			$ 150,000
Chief Medical Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Labor and Related Expense			290,000
Retention Bonus Payable			100,000
Chief Scientific Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Labor and Related Expense			$ 315,000
Maximum Percentage Of Bonus From Base Salary			30.00%

Subsequent Event - Additional Information (Details) - Subsequent Event [Member]	Feb. 10, 2015 USD ($)
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage	20.00%
Officers' Compensation	$ 420,000
Chief Business Officer [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage	3.00%
Officers' Compensation	$ 360,500